ArticleBMC health services research2019

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy.

Gianluca Furneri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.